A predictive genetic signature for response to fluoropyrimidine-based neoadjuvant chemoradiation in clinical Stage II and III rectal cancer

A predictive genetic signature for response to fluoropyrimidine-based neoadjuvant chemoradiation in clinical Stage II and III rectal cancer

PurposePreoperative chemoradiation is currently the standard of care for patients with clinical stage II and III rectal cancer but only about 45% of patients achieve tumor downstaging and less than 20% of patients achieve a pathologic complete response. Better methods to stratify patients according...

Full description

Bibliographic Details
Main Authors: Jason eChan, Michael eKinsella, Joseph eWillis, Huankai eHu, Harry eReynolds, Conor eDelaney, Andrea eMcCulla, Steve eDeharo, Miika eAhdesmaki, Wendy Louise Allen, Patrick eJohnston, Timothy James Kinsella
Format: Article
Language:English
Published: Frontiers Media S.A. 2013-11-01
Series:Frontiers in Oncology
Subjects:
Rectal Neoplasms
UBC
Gene array
ubiquination
EHBP1
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00288/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00288/full

Similar Items